ScholarIQanswers from OpenAlex & ORCID
Margaret von Mehren
ResearcherPublications, citations & collaboration network
Margaret von Mehren is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Margaret von Mehren have?
ScholarIQindexed works
Margaret von Mehren has 478 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Margaret von Mehren have?
ScholarIQcitation count
Margaret von Mehren has 34,569 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Margaret von Mehren?
ScholarIQh-index
Margaret von Mehren has an h-index of 76 in OpenAlex.
What is the i10-index of Margaret von Mehren?
ScholarIQi10-index
Margaret von Mehren has an i10-index of 219 in OpenAlex.
What is the ORCID of Margaret von Mehren?
ScholarIQorcid
The ORCID for Margaret von Mehren is on the source record.
What is the OpenAlex record for Margaret von Mehren?
ScholarIQopenalex
The OpenAlex for Margaret von Mehren is on the source record.
What are the most-cited papers on Margaret von Mehren?
ScholarIQmost cited works
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
George D. Demetri, Margaret von Mehren, Cristina R. Antonescu, Ronald P. DeMatteo, Kristen N. Ganjoo, Robert G. Maki, Peter W. T. Pisters, Chandrajit P. Raut, Richard F. Riedel, Scott M. Schuetze, Hema Sundar, Jonathan C. Trent, Jeffrey D. Wayne
Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Margaret von Mehren, John M. Kane, Mark Agulnik, Marilyn M. Bui, Janai R. Carr, Edwin Choy, Mary Connelly, Sarah Dry, Kristen N. Ganjoo, Ricardo González, Ashley M. Holder, Jade Homsi, Vicki L. Keedy, Ciara M. Kelly, Edward Kim, David A. Liebner, Martin D. McCarter, Sean V. McGarry, Nathan W. Mesko, Christian F. Meyer, Alberto S. Pappo, Amanda Parkes, Ivy A. Petersen, Seth M. Pollack, Matthew M. Poppe, Richard F. Riedel, Scott M. Schuetze, Jacob E. Shabason, Jason K. Sicklick, Matthew B. Spraker, Melissa N. Zimel, Lisa E. Hang, Hema Sundar, Mary Anne Bergman
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial
George D. Demetri, Margaret von Mehren, Robin L. Jones, Martee L. Hensley, Scott M. Schuetze, Arthur P. Staddon, Mohammed Milhem, A. Elias, Kristen N. Ganjoo, Hussein A. Tawbi, Brian Andrew Van Tine, Alexander I. Spira, Andrew Dean, Nushmia Z. Khokhar, Youn Choi Park, Roland E. Knoblauch, Trilok Parekh, Robert G. Maki, Shreyaskumar Patel
Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
Margaret von Mehren, R. Lor Randall, Robert S. Benjamin, Sarah G Boles, Marilyn M. Bui, Kristen N. Ganjoo, Suzanne George, Ricardo J. Gonzalez, Martin J. Heslin, John M. Kane, Vicki L. Keedy, Edward Kim, Henry Koon, Joel L. Mayerson, Martin McCarter, Sean V. McGarry, Christian Meyer, Zachary S. Morris, Richard J. O’Donnell, Alberto S. Pappo, I. Benjamin Paz, Ivy A. Petersen, John D. Pfeifer, Richard F. Riedel, Bernice Ruo, Scott M. Schuetze, William D. Tap, Jeffrey D. Wayne, Mary Anne Bergman, Jillian L. Scavone
Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules
George D. Demetri, Sant P. Chawla, Margaret von Mehren, Paul S. Ritch, Laurence H. Baker, Jean‐Yves Blay, Kenneth R. Hande, Mary Lou Keohan, Brian L. Samuels, Scott M. Schuetze, Claudia Lebedinsky, Yusri Elsayed, Miguel Izquierdo, Javier Gómez‐Román, Youn C. Park, Axel Le Cesne